Skip to main content
Top
Published in: Diabetologia 2/2006

01-02-2006 | Article

Plasma cytokine levels in young and elderly twins: genes versus environment and relation to in vivo insulin action

Authors: L. Grunnet, P. Poulsen, B. Klarlund Pedersen, T. Mandrup-Poulsen, A. Vaag

Published in: Diabetologia | Issue 2/2006

Login to get access

Abstract

Aims/hypothesis

We studied the impact of genetic versus pre- and postnatal environmental factors on the plasma levels of IL6, TNF and the soluble TNF receptor superfamily, member 1A (TNFRSF1A, previously known as TNF receptor type1 [TNFR1]).

Materials and methods

Using the hyperinsulinaemic–euglycaemic clamp, we assessed the association between cytokine levels and both peripheral insulin sensitivity and hepatic glucose production. Fasting plasma IL6, TNF and soluble TNFRSF1A levels were measured using ELISA in 55 young and 43 elderly twin pairs.

Results

Plasma IL6 and TNF were influenced by genetic factors in young and elderly twins respectively, while no significant impact of genetics was found for soluble TNFRSF1A. Significant intra-twin pair correlations between birthweight and both IL6 and soluble TNFRSF1A levels were found. In addition to the effect of birthweight on IL6, age and fat % also significantly influenced IL6 levels, whereas soluble TNFRSF1A levels were significantly influenced by zygosity, age, fat % and sex. Plasma soluble TNFRSF1A was associated with higher plasma NEFA and to some extent with reduced insulin sensitivity. Plasma IL6 was associated positively with basal NEFA. TNF level was not associated with in vivo glucose or fat metabolism after correction for known confounders.

Conclusions/interpretation

Plasma IL6 and soluble TNFRSF1A are influenced by the intrauterine environment. We found some evidence of a genetic component for TNF and IL6 in young and elderly twins respectively. Plasma IL6 may influence basal lipolysis, but neither plasma TNF nor IL6 levels are independently associated with hepatic or peripheral insulin action. Nevertheless, plasma soluble TNFRSF1A may play some role in the control of insulin action.
Literature
1.
go back to reference Poulsen P, Vaag A, Beck-Nielsen H (1999) Does zygosity influence the metabolic profile of twins? A population based cross sectional study. BMJ 319:151–154PubMed Poulsen P, Vaag A, Beck-Nielsen H (1999) Does zygosity influence the metabolic profile of twins? A population based cross sectional study. BMJ 319:151–154PubMed
2.
go back to reference Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA (1996) The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest 97:1111–1116PubMed Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA (1996) The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest 97:1111–1116PubMed
3.
go back to reference Bastard JP, Maachi M, Van Nhieu JT et al. (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87:2084–2089PubMedCrossRef Bastard JP, Maachi M, Van Nhieu JT et al. (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87:2084–2089PubMedCrossRef
4.
go back to reference Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665–668PubMedCrossRef Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665–668PubMedCrossRef
5.
go back to reference Hotamisligil GS (1999) Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 107:119–125PubMedCrossRef Hotamisligil GS (1999) Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 107:119–125PubMedCrossRef
6.
go back to reference Hotamisligil GS, Spiegelman BM (1994) Tumor necrosis factor alpha: a key component of the obesity–diabetes link. Diabetes 43:1271–1278PubMedCrossRef Hotamisligil GS, Spiegelman BM (1994) Tumor necrosis factor alpha: a key component of the obesity–diabetes link. Diabetes 43:1271–1278PubMedCrossRef
7.
go back to reference Ronnemaa T, Pulkki K, Kaprio J (2000) Serum soluble tumor necrosis factor-alpha receptor 2 is elevated in obesity but is not related to insulin sensitivity: a study in identical twins discordant for obesity. J Clin Endocrinol Metab 85:2728–2732PubMedCrossRef Ronnemaa T, Pulkki K, Kaprio J (2000) Serum soluble tumor necrosis factor-alpha receptor 2 is elevated in obesity but is not related to insulin sensitivity: a study in identical twins discordant for obesity. J Clin Endocrinol Metab 85:2728–2732PubMedCrossRef
8.
go back to reference Straczkowski M, Kowalska I, Stepien A, Dzienis-Straczkowska S, Szelachowska M, Kinalska I (2002) Increased plasma-soluble tumor necrosis factor-alpha receptor 2 level in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes Care 25:1824–1828PubMedCrossRef Straczkowski M, Kowalska I, Stepien A, Dzienis-Straczkowska S, Szelachowska M, Kinalska I (2002) Increased plasma-soluble tumor necrosis factor-alpha receptor 2 level in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes Care 25:1824–1828PubMedCrossRef
9.
go back to reference Steensberg A, Fischer CP, Sacchetti M et al. (2003) Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 548:631–638PubMedCrossRef Steensberg A, Fischer CP, Sacchetti M et al. (2003) Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 548:631–638PubMedCrossRef
10.
go back to reference Febbraio M.A., Hiscock N., Sacchetti M., Fischer C.P., Pedersen B.K. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 2004; 53:1643–1648PubMedCrossRef Febbraio M.A., Hiscock N., Sacchetti M., Fischer C.P., Pedersen B.K. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 2004; 53:1643–1648PubMedCrossRef
11.
go back to reference Rotter V, Nagaev I, Smith U (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777–45784PubMedCrossRef Rotter V, Nagaev I, Smith U (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777–45784PubMedCrossRef
12.
go back to reference Kim HJ, Higashimori T, Park SY et al. (2004) Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060–1067PubMedCrossRef Kim HJ, Higashimori T, Park SY et al. (2004) Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060–1067PubMedCrossRef
13.
go back to reference Kanemaki T, Kitade H, Kaibori M et al. (1998) Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology 27:1296–1303PubMedCrossRef Kanemaki T, Kitade H, Kaibori M et al. (1998) Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology 27:1296–1303PubMedCrossRef
14.
go back to reference Neel JV (1962) Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”? Am J Hum Genet 14:353–362PubMed Neel JV (1962) Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”? Am J Hum Genet 14:353–362PubMed
16.
go back to reference Poulsen P, Levin K, Beck-Nielsen H, Vaag A (2002) Age-dependent impact of zygosity and birth weight on insulin secretion and insulin action in twins. Diabetologia 45:1649–1657PubMedCrossRef Poulsen P, Levin K, Beck-Nielsen H, Vaag A (2002) Age-dependent impact of zygosity and birth weight on insulin secretion and insulin action in twins. Diabetologia 45:1649–1657PubMedCrossRef
17.
go back to reference De Maat MP, Marie BE, Von Bornemann HJ, Bathum L, Jespersen J, Christensen K (2004) Genetic influence on inflammation variables in the elderly. Arterioscler Thromb Vasc Biol 24:2168–2173PubMedCrossRef De Maat MP, Marie BE, Von Bornemann HJ, Bathum L, Jespersen J, Christensen K (2004) Genetic influence on inflammation variables in the elderly. Arterioscler Thromb Vasc Biol 24:2168–2173PubMedCrossRef
18.
go back to reference Ling C, Poulsen P, Carlsson E et al (2004) Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. J Clin Invest 114:1518–1526PubMedCrossRef Ling C, Poulsen P, Carlsson E et al (2004) Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. J Clin Invest 114:1518–1526PubMedCrossRef
19.
go back to reference Poulsen P, Levin K, Petersen I, Christensen K, Beck-Nielsen H, Vaag A (2005) Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes 54:275–283PubMedCrossRef Poulsen P, Levin K, Petersen I, Christensen K, Beck-Nielsen H, Vaag A (2005) Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes 54:275–283PubMedCrossRef
20.
go back to reference Morling N (2003) Forensic genetics. Retsgenetik. Ugeskr Laeger 165:922–925 Morling N (2003) Forensic genetics. Retsgenetik. Ugeskr Laeger 165:922–925
21.
go back to reference Bring J, Wernroth L (1999) Inefficient analysis of twin data: is there an association between diabetes and birth weight? Diabetologia 42:898–899PubMedCrossRef Bring J, Wernroth L (1999) Inefficient analysis of twin data: is there an association between diabetes and birth weight? Diabetologia 42:898–899PubMedCrossRef
22.
go back to reference Neale MC, Cardon LR (1992) Data summary. In: Methodology for Genetic Studies of Twins and Families. NATO ASI series. Kluwer, Dordrecht, Boston, London, pp 35–53 Neale MC, Cardon LR (1992) Data summary. In: Methodology for Genetic Studies of Twins and Families. NATO ASI series. Kluwer, Dordrecht, Boston, London, pp 35–53
23.
go back to reference Krabbe KS, Pedersen M, Bruunsgaard H (2004) Inflammatory mediators in the elderly. Exp Gerontol 39:687–699PubMedCrossRef Krabbe KS, Pedersen M, Bruunsgaard H (2004) Inflammatory mediators in the elderly. Exp Gerontol 39:687–699PubMedCrossRef
24.
go back to reference Kubaszek A, Pihlajamaki J, Komarovski V et al. (2003) Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52:1872–1876PubMedCrossRef Kubaszek A, Pihlajamaki J, Komarovski V et al. (2003) Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52:1872–1876PubMedCrossRef
25.
go back to reference Vozarova B, Fernandez-Real JM, Knowler WC et al. (2003) The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 112:409–413PubMed Vozarova B, Fernandez-Real JM, Knowler WC et al. (2003) The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 112:409–413PubMed
26.
go back to reference Kubaszek A, Pihlajamaki J, Punnonen K, Karhapaa P, Vauhkonen I, Laakso M (2003) The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes 52:558–561PubMedCrossRef Kubaszek A, Pihlajamaki J, Punnonen K, Karhapaa P, Vauhkonen I, Laakso M (2003) The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes 52:558–561PubMedCrossRef
27.
go back to reference Kubaszek A, Pihlajamaki J, Komarovski V et al. (2003) Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52:1872–1876PubMedCrossRef Kubaszek A, Pihlajamaki J, Komarovski V et al. (2003) Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52:1872–1876PubMedCrossRef
28.
go back to reference Day CP, Grove J, Daly AK, Stewart MW, Avery PJ, Walker M (1998) Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia 41:430–434PubMedCrossRef Day CP, Grove J, Daly AK, Stewart MW, Avery PJ, Walker M (1998) Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia 41:430–434PubMedCrossRef
29.
go back to reference Sheu WH, Lee WJ, Lin LY, Chang RL, Chen YT (2001) Tumor necrosis factor alpha -238 and -308 polymorphisms do not associate with insulin resistance in hypertensive subjects. Metabolism 50:1447–1451PubMedCrossRef Sheu WH, Lee WJ, Lin LY, Chang RL, Chen YT (2001) Tumor necrosis factor alpha -238 and -308 polymorphisms do not associate with insulin resistance in hypertensive subjects. Metabolism 50:1447–1451PubMedCrossRef
30.
go back to reference Coppack SW (2001) Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60:349–356PubMed Coppack SW (2001) Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60:349–356PubMed
31.
go back to reference Petersen AM, Pedersen BK (2005) The anti-inflammatory effect of exercise. J Appl Physiol 98:1154–1162PubMedCrossRef Petersen AM, Pedersen BK (2005) The anti-inflammatory effect of exercise. J Appl Physiol 98:1154–1162PubMedCrossRef
32.
go back to reference Dzienis-Straczkowska S, Straczkowski M, Szelachowska M, Stepien A, Kowalska I, Kinalska I (2003) Soluble tumor necrosis factor-alpha receptors in young obese subjects with normal and impaired glucose tolerance. Diabetes Care 26:875–880PubMedCrossRef Dzienis-Straczkowska S, Straczkowski M, Szelachowska M, Stepien A, Kowalska I, Kinalska I (2003) Soluble tumor necrosis factor-alpha receptors in young obese subjects with normal and impaired glucose tolerance. Diabetes Care 26:875–880PubMedCrossRef
33.
go back to reference Pedersen M, Bruunsgaard H, Weis N et al. (2003) Circulating levels of TNF-alpha and IL-6—relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev 124:495–502PubMedCrossRef Pedersen M, Bruunsgaard H, Weis N et al. (2003) Circulating levels of TNF-alpha and IL-6—relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev 124:495–502PubMedCrossRef
34.
go back to reference Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9:414–417PubMed Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9:414–417PubMed
35.
go back to reference Febbraio MA, Pedersen BK (2002) Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16:1335–1347PubMedCrossRef Febbraio MA, Pedersen BK (2002) Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16:1335–1347PubMedCrossRef
36.
go back to reference Pedersen BK, Steensberg A, Keller P et al. (2003) Muscle-derived interleukin-6: lipolytic, anti-inflammatory and immune regulatory effects. Pflugers Arch 446:9–16PubMed Pedersen BK, Steensberg A, Keller P et al. (2003) Muscle-derived interleukin-6: lipolytic, anti-inflammatory and immune regulatory effects. Pflugers Arch 446:9–16PubMed
37.
go back to reference Vaag A, Henriksen JE, Beck-Nielsen H (1992) Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Invest 89:782–788PubMedCrossRef Vaag A, Henriksen JE, Beck-Nielsen H (1992) Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Invest 89:782–788PubMedCrossRef
38.
go back to reference Vaag A, Henriksen JE, Madsbad S, Holm N, Beck-Nielsen H (1995) Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest 95:690–698PubMed Vaag A, Henriksen JE, Madsbad S, Holm N, Beck-Nielsen H (1995) Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest 95:690–698PubMed
39.
go back to reference Barker DJ, Bull AR, Osmond C, Simmonds SJ (1990) Fetal and placental size and risk of hypertension in adult life. BMJ 301:259–262PubMed Barker DJ, Bull AR, Osmond C, Simmonds SJ (1990) Fetal and placental size and risk of hypertension in adult life. BMJ 301:259–262PubMed
40.
go back to reference Lindmark E, Diderholm E, Wallentin L, Siegbahn A (2001) Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 286:2107–2113PubMedCrossRef Lindmark E, Diderholm E, Wallentin L, Siegbahn A (2001) Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 286:2107–2113PubMedCrossRef
Metadata
Title
Plasma cytokine levels in young and elderly twins: genes versus environment and relation to in vivo insulin action
Authors
L. Grunnet
P. Poulsen
B. Klarlund Pedersen
T. Mandrup-Poulsen
A. Vaag
Publication date
01-02-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0080-8

Other articles of this Issue 2/2006

Diabetologia 2/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.